Internal Reference Number: FOI_6878
Date Request Received: 21/11/2022 00:00:00
Date Request Replied To: 22/11/2022 00:00:00
This response was sent via: By Email
Request Summary: Pre-eclampsia treatment
Request Category: Companies
Question Number 1: Pre-eclampsia is a condition affecting up to one in ten pregnancies, and can lead to serious complications for both mother and baby if not monitored and treated. In cases of pre-eclampsia, levels of cental growth factor (PlGF) in the blood can be abnormally low and a sign that the placenta is not developing properly. 1.Is your trust currently implementing PIGF-based testing to diagnose pre-eclampsia? | |
Answer To Question 1: No | |
Question Number 2: If so, how many tests has your trust implemented each year over the past 5 calendar years (2018, 2019, 2020, 2021, 2022 YTD) | |
Answer To Question 2: n/a | |
Question Number 3: If not, please outline the reasons why your trust is not currently implementing PIGF-based testing. Please answer with reference to the fact that PIGF-based testing has been recommended by National Institute of Health and Care Excellence (NICE) to both rule in and rule out pre-eclampsia for people presenting with suspected symptoms. | |
Answer To Question 3: Pilot was instigated for 12 months, low uptake in tests due to population therefore trust did not pursue this test. | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.